Scientists Advance Epigenome Editing as Safer Alternative to DNA Modification

In January 2026, a team at the University of New South Wales demonstrated that a modified CRISPR system could reactivate silenced genes in human cells — not by cutting DNA strands, as conventional CRISPR does, but by brushing away tiny chemical clusters called methyl groups that act as molecular switches [1]. "We showed very clearly that if you brush the cobwebs off, the gene comes on," said Professor Merlin Crossley, the study's lead author [1]. When methyl groups were reattached, the genes shut down again, confirming these compounds function as reversible genetic dimmers.

The result added momentum to a field that has been building for years: epigenome editing, which modifies how genes are expressed without altering the underlying DNA sequence. Unlike traditional CRISPR-Cas9, which cuts both strands of the double helix to knock out or replace genes, epigenome editors use a catalytically dead version of Cas9 (dCas9) fused to proteins that add or remove chemical marks — DNA methylation, histone acetylation, histone methylation — to turn genes up or down [2][3]. The approach is generating intense scientific interest, significant venture capital, and a growing debate about whether it truly delivers on the promise of safer genetic medicine.

The Science: How Epigenome Editors Work

Traditional genome editing with CRISPR-Cas9 introduces double-stranded DNA breaks at targeted locations, then relies on the cell's own repair machinery to fix the cut — a process that can produce insertions, deletions, or chromosomal rearrangements [4]. Epigenome editing sidesteps this entirely. The key platforms include:

• dCas9-KRAB: A deactivated Cas9 protein fused to the KRAB repressor domain, which recruits histone-modifying complexes to silence target genes [2].
• dCas9-DNMT3A/3L: dCas9 fused to DNA methyltransferases that write methyl marks directly onto gene promoters, physically blocking transcription [3].
• CRISPRoff: A combinatorial tool fusing dCas9 to both KRAB and the DNMT3A-DNMT3L enzyme complex, achieving more durable silencing than either component alone [5].
• Zinc finger protein (ZFP) and TALE-based editors: Older DNA-binding platforms now being repurposed to deliver epigenetic effectors with high specificity [6].

Because none of these systems cut DNA, they avoid the primary source of genotoxicity — chromosomal translocations and large deletions — associated with Cas9 nuclease editing [2][4].

Durability: Do the Edits Stick?

A central question for any epigenome therapy is persistence. If the chemical marks wash off after a few cell divisions, patients would need repeated treatments — undermining the economic and practical case for the approach.

The evidence so far is encouraging. A landmark 2024 study published in Nature by researchers at the San Raffaele–Telethon Institute for Gene Therapy in Milan demonstrated what they called "hit-and-run" epigenome editing: a single injection of lipid nanoparticles carrying epigenome editor mRNAs reduced circulating PCSK9 protein levels by up to 75% in mice, with silencing persisting for nearly one year [6]. Critically, when the researchers forced liver regeneration through partial hepatectomy three months after treatment — triggering extensive cell division — the epigenetic marks and gene silencing were maintained, demonstrating heritability through mitosis [6].

In cell culture, CRISPRoff-mediated silencing has been maintained for over 450 cell divisions in HEK293T cells [5]. More recent work has shown that CRISPRoff silencing persists through T-cell stimulation cycles and in vivo adoptive transfer, a finding with direct relevance to cancer immunotherapy [5].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Research output in the field has grown sharply, with over 24,000 papers published on epigenome editing since 2011, peaking at 3,843 publications in 2024 [7].

Whether epigenetic marks transmit across generations in mammals remains less clear. Environmental epigenetic changes can be passed beyond the second generation in animal models [8], but no study has demonstrated that therapeutically introduced epigenome edits are inherited by offspring — a distinction with major regulatory implications.

The Clinical Pipeline: From Lab Bench to First-in-Human

The epigenome editing field is entering its clinical phase, though it remains far behind conventional CRISPR therapy in terms of pipeline depth. As of early 2026:

• Tune Therapeutics is the most advanced, with its lead candidate Tune-401 — an epigenetic silencing therapy for chronic hepatitis B — at clinical stage. In January 2025, the company closed a $175 million Series B round led by New Enterprise Associates, Regeneron Ventures, and Hevolution Foundation, bringing its total funding past $215 million [9][10].
• Epicrispr Biotechnologies (formerly Epic Bio) has dosed the first patient in a global first-in-human clinical trial of EPI-321, designed to silence DUX4 expression through epigenetic modulation for facioscapulohumeral muscular dystrophy (FSHD) [11].
• Chroma Medicine has raised $260 million across seed, Series A, and Series B rounds. At ASCGT 2023, the company reported that its targeted epigenetic editor achieved 99% silencing of PCSK9, durable for at least five months in mice [12][13].
• Navega Therapeutics is pursuing epigenetic silencing of the NaV1.7 sodium channel (SCN9A) for chronic pain using ZFP- and dCas9-based tools fused to KRAB [14].
• Epigenic Therapeutics completed a $60 million Series B in 2025 to advance its own epigenetic medicine programs [15].

For comparison, conventional CRISPR-Cas9 therapies are substantially further along. The global CRISPR-based gene editing market was valued at approximately $4 billion in 2024 and is projected to exceed $7 billion in 2025 [16]. Vertex Pharmaceuticals' Casgevy, the first CRISPR gene therapy approved for sickle cell disease, has been on the market since late 2023 at a list price of $2.2 million per patient [17].

Source: Company press releases, PitchBook

Data as of Jan 15, 2025CSV

Off-Target Risks: Different, Not Absent

Proponents of epigenome editing frequently emphasize that it avoids the DNA double-strand breaks that make Cas9 nuclease editing genotoxic. This is true — but it does not mean off-target effects are eliminated.

dCas9-based editors can bind to unintended genomic locations, depositing repressive marks at off-target sites. A 2025 study profiling CRISPR/dCas9 epigenome editors found "a complex link between on and off target effects," indicating that guide RNA design must be carefully optimized to minimize spurious silencing [18]. Standard Cas9 nuclease is known to tolerate up to three mismatches between the guide RNA and genomic DNA [4], and while dCas9 does not cut at these sites, it can still recruit epigenetic modifiers to them.

In functional screens, CRISPRi (CRISPR interference, a dCas9-KRAB system) produced "strong confounding fitness effects" at off-target loci — meaning the tool silenced genes that affected cell survival at unintended locations [19]. Filtering guide RNA libraries using specificity scoring tools like GuideScan reduced but did not eliminate these effects [19].

The hit-and-run study from San Raffaele reported that transient increases in liver enzymes observed in treated mice were "likely caused by the LNP formulation, not the ZFP-ETRs" [6], but long-term safety data in larger animals and humans remain scarce.

The Cancer Question: Could Epigenome Editing Cause Harm?

The most serious safety concern may be the most fundamental: epigenetic silencing of tumor-suppressor genes is itself a hallmark of cancer. Aberrant DNA methylation at the promoters of genes like p16, BRCA1, and MLH1 is a common early event in oncogenesis [20][21]. If an epigenome editor deposits methyl marks at the wrong location — even transiently — the consequences could include uncontrolled cell proliferation.

This is not a hypothetical risk. Research has established that epigenetic silencing of tumor suppressors is "thought to be an early, driving event in the oncogenic process" [20]. The question is whether therapeutic epigenome editors, designed to target specific loci, can achieve the specificity needed to avoid inadvertently silencing protective genes.

No peer-reviewed study has yet documented tumor formation caused by an epigenome editing tool. But the field is young, and long-term carcinogenicity studies of the kind required for FDA approval have not been completed. Some researchers argue that the "safer" framing popular in press coverage and investor presentations is premature without this data [2][22].

The Money Trail: Venture Capital Bets Big

Private investment in epigenome editing has accelerated sharply since 2021. Chroma Medicine launched that year with $125 million and has since raised a total of $260 million [12][13]. Tune Therapeutics started with $40 million in 2021 and crossed $215 million with its 2025 Series B [9][10]. Epicrispr, Navega, and Epigenic round out a cohort that has collectively raised well over $600 million.

These figures remain modest compared to the broader gene therapy market. The global gene therapy market was valued at over $7 billion in 2024 [16], and single approved products like Casgevy generate hundreds of millions in revenue. But the trajectory is steep: Tune's $175 million Series B was one of the largest biotech financing rounds of early 2025 [10].

The investor thesis is straightforward: if epigenome editors prove durable and safe, they could capture market share from riskier permanent editing approaches while expanding into diseases — like chronic infections, neurodegeneration, and pain — where reversibility is a feature rather than a limitation.

Who Benefits First — and Who Gets Left Behind?

The first clinical applications of epigenome editing are concentrated in diseases prevalent in wealthy countries: chronic hepatitis B (Tune Therapeutics), FSHD (Epicrispr), hypercholesterolemia (Chroma Medicine), and chronic pain (Navega Therapeutics) [9][11][12][14]. This pattern mirrors the broader gene therapy field, where approved products target conditions like sickle cell disease but remain financially inaccessible to the populations most affected.

The access gap is stark. More than 60% of the 120 million people worldwide with sickle cell disease live in sub-Saharan Africa [17]. Casgevy's $2.2 million price tag is orders of magnitude beyond what healthcare systems in those countries can afford. Modeling studies have estimated that the maximum affordable price for gene therapy in Uganda is approximately $700 per patient — a 3,000-fold gap [23]. Only three specialized clinical centers capable of administering current gene therapies serve all of sub-Saharan Africa [17].

Epigenome editing's lower manufacturing complexity — particularly with hit-and-run approaches that require only transient delivery of mRNA rather than permanent viral vectors — could theoretically reduce costs. But no company has announced pricing strategies for low- and middle-income countries, and the infrastructure requirements for mRNA-LNP therapies, while less demanding than ex vivo cell manipulation, remain substantial.

Regulatory Limbo: How Should Reversible Edits Be Governed?

Current FDA and EMA regulatory frameworks for gene therapy were designed with permanent genetic modifications in mind. The FDA classifies gene therapies under its Center for Biologics Evaluation and Research (CBER) and requires long-term follow-up studies — typically 15 years for integrating vectors — to monitor for delayed adverse events [24]. The EMA's guidelines for Advanced Therapy Medicinal Products (ATMPs) similarly focus on products that "contain or consist of recombinant genes" and impose long-term pharmacovigilance requirements [24].

Epigenome editors fit awkwardly into these categories. They do not alter the DNA sequence, and their effects are — at least in principle — reversible. Some scientists and companies have argued that this should warrant a distinct regulatory pathway with shorter follow-up requirements, though no formal rule change has been proposed by either agency [22][24].

The 2023 paper "Is epigenome editing non-inheritable?" raised the key regulatory question directly: if epigenetic edits do not pass to offspring, the ethical and regulatory concerns that apply to germline genome editing may not apply [22]. But the authors cautioned that the evidence for non-heritability is incomplete, and that regulators should not relax oversight prematurely.

For now, companies like Tune and Epicrispr are navigating existing gene therapy regulatory pathways, accepting the same IND requirements and clinical trial frameworks that apply to permanent CRISPR therapies [9][11].

The Case for Permanent Editing: When Reversibility Is a Bug

Not everyone in the field sees epigenome editing as an improvement. For certain diseases, the reversibility that makes epigenetic approaches attractive is precisely what makes them inadequate.

Sickle cell disease is the clearest example. Patients carry a single-nucleotide mutation in the beta-globin gene that causes hemoglobin to polymerize under low-oxygen conditions, deforming red blood cells. A permanent correction of this mutation — as Casgevy achieves by reactivating fetal hemoglobin through a permanent edit to the BCL11A enhancer — provides lifelong benefit from a single treatment [17]. An epigenetic approach that might wear off after months or years would require retreatment, reintroducing cost, risk, and patient burden.

Similar arguments apply to severe combined immunodeficiency (SCID), Duchenne muscular dystrophy caused by exon deletions, and certain inborn errors of metabolism where the underlying genetic defect is unambiguous and permanent correction is the therapeutic goal [2][3].

The counterargument from epigenome editing proponents is that many conditions — chronic pain, viral infections, neurodegeneration, metabolic disorders — do not require permanent correction and may benefit from adjustable, reversible modulation [3][25]. For prion diseases, where toxic protein accumulation must be stopped but the gene's normal function may be needed later, the ability to turn silencing on and off could be essential [6].

The field's future likely involves both approaches coexisting, with the choice between permanent and reversible editing determined by disease biology rather than ideology.

What Comes Next

Epigenome editing is at an inflection point. The preclinical data — durable silencing lasting nearly a year in mice, persistence through hundreds of cell divisions, the first patients dosed in human trials — represents genuine scientific progress [5][6][11]. But the gap between mouse data and approved human therapeutics is vast, and the field's two biggest unanswered questions — long-term safety and manufacturing cost — will determine whether epigenome editors become a standard clinical tool or remain a niche technology.

The next 18 to 24 months will be decisive. Readouts from Epicrispr's FSHD trial and Tune's hepatitis B program will provide the first human efficacy and safety data. Regulatory agencies will need to clarify whether reversible epigenetic modifications warrant a distinct oversight framework. And the question of who can afford these therapies — and who cannot — will only grow more urgent as the technology matures.